Quince Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
QNCX$31.73+8.1%Stored close · as of Oct 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| For the three months ended September 30, 2024 and 2023 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid in · Accumulated OtherComprehensive · Accumulated · Total Stockholders' | |||||||||||||
| Shares · Amount | |||||||||||||
| Balance as of June 30, 2024 | 43,276,606 | $43 | $404,360 | $1,087 | $(358,522) | $46,968 | |||||||
| Stock based compensation | — | — | 1,124 | — | 1,124 | ||||||||
| Foreign currency translation adjustment | — | — | — | 2,158 | — | 2,158 | |||||||
| Unrealized gain (loss) on available for sale investments | — | — | — | 174 | — | 174 | |||||||
| Net loss | — | — | — | — | (5,492) | (5,492) | |||||||
| Balance September 30, 2024 | 43,276,606 | $43 | $405,484 | $3,419 | $(364,014) | $44,932 | |||||||
| Balance as of June 30, 2023 | 36,327,995 | $36 | $391,990 | $257 | $(305,399) | $86,884 | |||||||
| Issuance of common stock on exercise of stock options and vesting of restricted stock units | 70,394 | — | 28 | — | — | 28 | |||||||
| Restricted stock award retirement | (54,757) | — | (18) | — | — | (18) | |||||||
| Stock based compensation | — | — | 1,331 | — | — | 1,331 | |||||||
| Foreign currency translation adjustment | — | — | — | 158 | — | 158 | |||||||
| Unrealized gain (loss) on available for sale investments | — | — | — | 101 | — | 101 | |||||||
| Net loss | — | — | — | — | (5,351) | (5,351) | |||||||
| Balance September 30, 2023 | 36,343,632 | $36 | $393,331 | $516 | $(310,750) | $83,133 | |||||||
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
| For the nine months ended September 30, 2024 and 2023 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid inCapital · Accumulated OtherComprehensiveIncome / (Loss) · AccumulatedDeficit · Total Stockholders'Equity | |||||||||||
| Shares · Amount | |||||||||||
| Balance December 31, 2023 | 42,973,215 | $43 | $401,638 | $3,047 | $(319,644) | $85,084 | |||||
| Issuance of common stock on exercise of stock options and vesting of restricted stock units | 303,391 | — | 225 | — | — | 225 | |||||
| Stock based compensation | — | — | 3,621 | — | — | 3,621 | |||||
| Foreign currency translation adjustment | — | — | — | 203 | — | 203 | |||||
| Unrealized gain (loss) on available for sale investments | — | — | — | 169 | — | 169 | |||||
| Net loss | — | — | — | — | (44,370) | (44,370) | |||||
| Balance September 30, 2024 | 43,276,606 | $43 | $405,484 | $3,419 | $(364,014) | $44,932 | |||||
| Balance December 31, 2022 | 36,136,480 | $36 | $389,105 | $(289) | $(288,259) | $100,593 | |||||
| Issuance of common stock on exercise of stock options and vesting of restricted stock units | 270,445 | — | 110 | — | — | 110 | |||||
| Restricted stock award retirement | (63,293) | — | (18) | — | — | (18) | |||||
| Stock based compensation | — | — | 4,134 | — | — | 4,134 | |||||
| Foreign currency translation adjustment | — | — | — | 309 | — | 309 | |||||
| Unrealized gain (loss) on available for sale investments | — | — | — | 496 | — | 496 | |||||
| Net loss | — | — | — | — | (22,491) | (22,491) | |||||
| Balance September 30, 2023 | 36,343,632 | $36 | $393,331 | $516 | $(310,750) | $83,133 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.